trial
as of 2026-07-01The Efficacy of Escitalopram for Negative Symptoms in Schizophrenia
NCTId NCT00148447
at a glance
Synthesized from structured facts only — each point cited above.
Design & status
Phase
Phase 3
Status
Completed
Enrollment
40
Study type
Interventional
Allocation
Randomized
Model
Parallel
Masking
Double
Start
2004-11
Primary completion
—
Eligibility
ALL · 18 Years · 60 Years
Interventions & indications
Drugs
Indications
Sponsors
BeerYaakov Mental Health CenterLead Sponsor
Lundbeck Canada Inc.Collaborator
Investigators
2
Iulian Iancu, M.D.Principal Investigator
Moshe Rehavi, Ph.D.Study Chair
Sites
1 total
Beer Yaakov, Israel
Facts & assertions
3 sourced
Enrollment
40
Phase
PHASE3
Status
COMPLETED
relationships
The graph out of here
drug
drug
lead_sponsor
collaborator
company
indication
investigator
person
person